Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.92 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3057575 | 0.96 | HRH3 (1.00) | HRH3SLC6A4SLC6A2SLC6A3SCN9A | |
| Trifluoroacetic Acid SCHEMBL2963867 | 0.90 | HRH3 (0.88) | HRH3SLC6A4SLC6A2SLC6A3SCN9A | |
| SCHEMBL2977048 | 0.81 | HRH3 (1.00) | HRH3SLC6A4SLC6A2SLC6A3SCN9A | |
| SCHEMBL2970126 | 0.81 | HRH3 (0.92) | HRH3SLC6A4SLC6A2SLC6A3SCN9A | |
| SCHEMBL3057577 | 0.80 | HRH3 (0.63) | HRH3SLC6A4SLC6A2SLC6A3SCN9A | |
| SCHEMBL3062757 | 0.79 | HRH3 (0.62) | HRH3SLC6A4SLC6A2SLC6A3SCN9A | |
| SCHEMBL3082452 | 0.79 | HRH3 (1.00) | HRH3SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL2976112 | 0.79 | HRH3 (0.61) | HRH3SLC6A4SLC6A2SLC6A3SCN9A | |
| SCHEMBL3074418 | 0.79 | HRH3 (0.61) | HRH3SLC6A4SLC6A2SLC6A3SCN9A | |
| SCHEMBL3076012 | 0.78 | HRH3 (0.94) | HRH3SLC6A4SLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321729-B2 | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-26 | — | — | US | disclosed |
| US-20150087635-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-26 | — | — | US | disclosed |
| US-8940731-B2 | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-27 | — | — | US | disclosed |
| US-20140107105-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637520-B2 | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-28 | — | — | US | disclosed |
| US-20100267701-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087635-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885SLC6A4 639/4885SLC6A2 752/4885 |
| US-20100267701-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885SLC6A4 639/4885SLC6A2 752/4885 |
| US-20140107105-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885SLC6A4 639/4885SLC6A2 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.